RCG
GLMD icon

Rock Creek Group’s Galmed Pharmaceuticals GLMD Stock Holding History

Rock Creek Group’s Portfolio GLMD Stock Details GLMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-525
Closed -$327K – 189
2020
Q1 		$327K Buy
525
+50
+11% +$47.5K 0.18% 85
2019
Q4 		$494K Buy
475
+163
+52% +$140K 0.2% 94
2019
Q3 		$268K Sell
312
-6
-2% -$6.02K 0.13% 93
2019
Q2 		$420K Buy
+318
New +$410K 0.19% 89

Other funds holding GLMD

NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
II
Ibex Investors Denver, Colorado $152M AUM 19.17% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
RJA
Raymond James & Associates St Petersburg, Florida $164B AUM 33.91% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
VC
Voss Capital Houston, Texas $1.88B AUM 1.03% 1-Year Est. Return
PF
Phoenix Financial Givatayim, Israel $10.5B AUM 49.21% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Rock Creek Group's GLMD Position: Q2 2020 in Review

Rock Creek Group sold out of Galmed Pharmaceuticals (GLMD) in Q2 2020, closing a stake of 525 shares — an estimated $327K sold.

Rock Creek Group first reported a position in GLMD in Q2 2019 and held it in 4 quarters. The position peaked at $494K in Q4 2019. 25 funds tracked by Wall St. Rank hold GLMD as of Q2 2020.

  • Rock Creek Group reported no remaining Galmed Pharmaceuticals position as of Q2 2020 after selling out during the quarter.
  • Rock Creek Group sold 525 Galmed Pharmaceuticals shares in Q2 2020, an estimated $327K.
  • Rock Creek Group first reported a position in Galmed Pharmaceuticals in Q2 2019 and held it in 4 quarters.
  • Rock Creek Group's Galmed Pharmaceuticals position peaked at $494K in Q4 2019.
  • 25 funds tracked by Wall St. Rank held Galmed Pharmaceuticals as of Q2 2020.

Based on Rock Creek Group's 13F filing for Q2 2020, filed 13 Aug 2020.